Testing effectiveness (Phase 2)Study completedNCT01604824
What this trial is testing
Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene
Who this might be right for
Hypercholesterolemia
Regeneron Pharmaceuticals 23